Preliminary Study Evaluates Interleukin-1 Blockade for Patients with Severe Covid-19

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study – The Lancet Rheumatology

Commentaries: Expert reaction to study looking at use of arthritis drug anakinra in hospitalised patients with severe COVID-19 – Science Media Centre AND Small study of patients with severe COVID-19 treated with the arthritis drug anakinra finds clinical improvements – The Lancet